<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01973816</url>
  </required_header>
  <id_info>
    <org_study_id>2013/001/HP</org_study_id>
    <nct_id>NCT01973816</nct_id>
  </id_info>
  <brief_title>MEdical Versus SUrgical Treatments of Rectal Endometriosis</brief_title>
  <acronym>MESURE</acronym>
  <official_title>Randomized Trial Comparing Functional Digestive Outcomes Related to Two Types of Management of Rectal Endometriosis: Continuous Hormonal Treatment and Curative Surgery</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University Hospital, Rouen</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University Hospital, Rouen</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to determine whether, in women with deep endometriosis involving
      the rectum and not intending to get pregnant, continuous hormonal treatment would be followed
      by better digestive functional outcomes than curative rectal surgery. Are included women from
      35 to 50 years presenting with deep endometriosis infiltrating at least the muscular layer of
      the rectum and not having pregnancy intention.

      The main outcome concerns the quality of digestive function 24 after the onset of the
      treatment, assessed using a composite variable: patient considering that digestive function
      is normal AND the Knowles-Eccersley-Scott-Symptom Questionnaire (KESS score) &lt;7 AND the
      Gastrointestinal Quality of Life Index (GIQLI) score &gt;100.

      Secondary outcomes are: presence of severe constipation, increased frequency of daily bowel
      movements, anal incontinence, postoperative dysuria, Biberoglou &amp; Behrman score, quality of
      life SF36 score, KESS score, GIQLI, Wexner score of anal continence, Bristol stools score,
      the rate of postoperative complications, medical treatment adverse outcomes, the rate of
      additional endoscopic and surgical procedures.

      The randomization is central, once the physician asses the diagnosis, explain the study's
      principle and rece In the arm A, the patients received triptoreline and add back therapy by
      estradiol during 6 months, followed by daily intake of cyproterone acetate and add back
      therapy during 18 months.

      In the arm B, patients are managed by rectal surgery (depending on the surgeon choice: rectal
      shaving, rectal disc excision or colorectal resection) followed by the prevention of
      recurrences by daily intake of cyproterone acetate and add back therapy during 18 months.

      The number of subjects required is 78 (39 on each arm). Inclusions period is estimated at 24
      months. The length of the follow up is 24 months. The patients have 8 visits in the arm A,
      and 7 visits in the arm B.

      Eleven French tertiary referral centres will enrol patients in the trial.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date>November 2014</start_date>
  <completion_date type="Anticipated">November 2019</completion_date>
  <primary_completion_date type="Anticipated">March 2018</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Postoperative digestive function</measure>
    <time_frame>24 months</time_frame>
    <description>Composite variable: patient considering that digestive function is normal AND the Knowles-Eccersley-Scott-Symptom Questionnaire (KESS score) &lt;7 AND the Gastrointestinal Quality of Life Index (GIQLI) score &gt;100.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Unfavorable digestive functional outcome</measure>
    <time_frame>24 months</time_frame>
    <description>Presence of severe constipation (&lt;1 stool/5D), increased frequency of daily bowel movements (&gt;=3 stools/D), anal incontinence, postoperative dysuria</description>
  </secondary_outcome>
  <other_outcome>
    <measure>Assessment of digestive function</measure>
    <time_frame>24 months</time_frame>
    <description>The Knowles-Eccersley-Scott-Symptom Questionnaire (KESS score), the Gastrointestinal Quality of Life Index (GIQLI), Wexner score of anal continence, Bristol stools score.</description>
  </other_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">78</enrollment>
  <condition>Endometriosis</condition>
  <arm_group>
    <arm_group_label>Medical treatment</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>The patients received triptoreline and add back therapy by estradiol during 6 months, followed by daily intake of cyproterone acetate and add back therapy during 18 months.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Surgical</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>The patients are managed by rectal surgery (depending on the surgeon choice: rectal shaving, rectal disc excision or colorectal resection) followed by the prevention of recurrences by daily intake of cyproterone acetate and add back therapy during 18 months.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Triptoreline 11.25 i.v.; Estradiol 0.5% percutaneous gel;</intervention_name>
    <description>Triptoreline 11.25 administered for 3 months, two consecutive cures Estradiol administered daily for 6 months</description>
    <arm_group_label>Medical treatment</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>rectal shaving; rectal disc excision; colorectal resection</intervention_name>
    <arm_group_label>Surgical</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Cyproterone acetate 50 mg; estradiol 0.5% percutaneous</intervention_name>
    <description>Daily intake for 18 months</description>
    <arm_group_label>Medical treatment</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Estradiol 0.5% percutaneous gel; Cyproterone acetate 50 mg oral</intervention_name>
    <description>Daily intake during 24 months</description>
    <arm_group_label>Surgical</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Age 35-50

          -  No menopause

          -  Digestive complaints: defecation pain, dyskesia, diarrhea, constipation, rectorrhage

          -  Imaging assessment revealing deep endometriosis involving at least the muscular rectal
             layer

          -  No intention to get pregnant during the following 24 months

          -  Negative urinary pregnancy test

          -  Affiliated to the French Social Security System

        Exclusion Criteria:

          -  Pregnant women or during the breastfeeding

          -  Pregnancy intention or lack of efficient contraception

          -  Unexpected rectal endometriosis intraoperatively revealed

          -  Refus of one of treatments planned in the two arms

          -  Severe disease requiring surgical treatment in emergency (bowel occlusion, ureteral
             stenosis or hydronephrosis), severe dyspareunia

          -  Contraindications to hormonal treatment or surgery

          -  Major thromboembolic factors

          -  Antecedents of inflammatory bowel diseases, cancer or colorectal resection

          -  Vaginal hemorrhage with undetermined etiology
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>35 Years</minimum_age>
    <maximum_age>50 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Horace Roman, MD PhD</last_name>
    <phone>+33232888745</phone>
    <email>horace.roman@gmail.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>CHU d'AMIENS</name>
      <address>
        <city>Amiens</city>
        <zip>80054</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Sophie Sanguin, MD</last_name>
      <phone>+333 22 53 36 23</phone>
      <email>sanguinsophie@aol.com</email>
    </contact>
    <investigator>
      <last_name>Sophie Sanguin</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Service de Gynécologie, Obstétrique et Médecine de la Reproduction CHU de CLERMONT-FERRAND Hôpital ESTAING 1 place Lucie Aubrac</name>
      <address>
        <city>Clermont-ferrand</city>
        <zip>63000</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Michel Canis, MD PhD</last_name>
      <phone>+334 73 75 01 38</phone>
      <email>mcanis@chu-clermontferrand.fr</email>
    </contact>
    <investigator>
      <last_name>Nicolas Bourdel, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>CHU de DIJON</name>
      <address>
        <city>Dijon</city>
        <zip>21079</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Paul Sagot, MD PhD</last_name>
      <phone>+333 80 29 38 52</phone>
      <email>paul.sagot@chu-dijon.fr</email>
    </contact>
    <investigator>
      <last_name>Paul Sagot</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Service de Gynécologie-Obstétrique AP-HP Hôpital du KREMLIN BICETRE</name>
      <address>
        <city>Kremlin Bicetre</city>
        <zip>94270</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Herve Fernandez, MD PhD</last_name>
      <phone>+331 45 21 77 01</phone>
      <email>herve.fernandez@bct.aphp.fr</email>
    </contact>
    <investigator>
      <last_name>Herve Fernandez, MDPhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hôpital du CHESNAY</name>
      <address>
        <city>Le Chesnay</city>
        <zip>78157</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Pierre Panel, MD</last_name>
      <phone>+331 39 63 97 33</phone>
      <email>PPANEL@ch-versailles.fr</email>
    </contact>
    <investigator>
      <last_name>Pierre Panel</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Clinique Gynécologique CHRU de LILLE</name>
      <address>
        <city>Lille</city>
        <zip>59037</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Chrystele Rubod, MCUPH</last_name>
      <phone>+333 20 44 67 57</phone>
      <email>chrystele.rubod@chu-lille.fr</email>
    </contact>
    <investigator>
      <last_name>Chrystele Rubod</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Service de Gynécologie-Obstétrique CHU de NIMES</name>
      <address>
        <city>Nimes</city>
        <zip>39900</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>RenaudTayrac de Tayrac, MD PhD</last_name>
      <phone>+336 03 26 32 32</phone>
      <email>renaud.detayrac@chu-nimes.fr</email>
    </contact>
    <investigator>
      <last_name>Renaud de Tayrac, MD PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hôpital de TENON</name>
      <address>
        <city>Paris</city>
        <zip>75020</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Emile Darai, MD PhD</last_name>
      <email>emile.darai@tnn.aphp.fr</email>
    </contact>
    <investigator>
      <last_name>Marcos Bellester</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Chi Poissy-St Germain En Laye Poissy</name>
      <address>
        <city>Poissy</city>
        <zip>78103</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Arnaud Fauconnier, MD PhD</last_name>
      <phone>+331 39 27 52 51</phone>
      <email>afauconnier@chi-poissy-st-germain.fr</email>
    </contact>
    <investigator>
      <last_name>Arnaud Fauconnier</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Clinique Gynécologique et Obstétricale</name>
      <address>
        <city>Rouen</city>
        <zip>76031</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Horace Roman, MD PhD</last_name>
      <phone>+33232888745</phone>
      <email>horace.roman@gmail.com</email>
    </contact>
    <investigator>
      <last_name>Horace Roman, MD PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>CHU de STRASBOURG STRASBOURG</name>
      <address>
        <city>Strasbourg</city>
        <zip>67000</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Arnaud Wattiez, MD PhD</last_name>
      <phone>+333 88 12 74 55</phone>
      <email>arnaud.wattiez@ircad.fr</email>
    </contact>
    <investigator>
      <last_name>Arnaud Wattiez</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>June 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>October 25, 2013</study_first_submitted>
  <study_first_submitted_qc>October 31, 2013</study_first_submitted_qc>
  <study_first_posted type="Estimate">November 1, 2013</study_first_posted>
  <last_update_submitted>June 13, 2017</last_update_submitted>
  <last_update_submitted_qc>June 13, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">June 14, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>deep endometriosis;</keyword>
  <keyword>rectal endometriosis;</keyword>
  <keyword>rectal shaving;</keyword>
  <keyword>colorectal resection;</keyword>
  <keyword>bowel endometriosis</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Endometriosis</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Estradiol</mesh_term>
    <mesh_term>Polyestradiol phosphate</mesh_term>
    <mesh_term>Cyproterone</mesh_term>
    <mesh_term>Cyproterone Acetate</mesh_term>
    <mesh_term>Estradiol 3-benzoate</mesh_term>
    <mesh_term>Estradiol 17 beta-cypionate</mesh_term>
    <mesh_term>Estradiol valerate</mesh_term>
    <mesh_term>Triptorelin Pamoate</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

